Literature DB >> 7574251

Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis.

A M Pou1, F L Rimell, J A Jordan, D L Shoemaker, J T Johnson, P Barua, J C Post, G D Ehrlich.   

Abstract

Pathologic material and the records of 29 patients with laryngeal papillomatosis were reviewed. The relationship between the type of human papillomavirus (HPV) and the presence of viral coinfections was correlated with clinical outcome. Using polymerase chain reaction, paraffin-embedded specimens were analyzed for the presence of HPV, Epstein-Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV). The HPV type could be identified in 24 patients' specimens. Twenty-one patients were infected with HPV type 6. The other 3 were infected with HPV type 11 or 16. Three patients developed squamous cell carcinoma, of whom 2 had HPV type 11 or 16. We found HSV, EBV, and CMV in 50%, 12.5%, and 0% of specimens, respectively. An aggressive clinical course was observed in 17 patients. Evidence of coinfection with other viruses was identified in 11 (65%) of these patients. In contrast, a benign clinical course was observed in 7 patients, of whom 2 (29%) had viral coinfections. We conclude that the HPV type and the presence of viral coinfections may be predictive of an aggressive clinical course.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574251     DOI: 10.1177/000348949510401002

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  22 in total

1.  Comparison of 16S rRNA gene PCR and BACTEC 9240 for detection of neonatal bacteremia.

Authors:  J A Jordan; M B Durso
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  Prognostic value of clinical findings in histologically verified adult-onset laryngeal papillomas.

Authors:  L M Aaltonen; J Peltomaa; H Rihkanen
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

Review 3.  Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  The Prevalence, Anatomic Distribution and Significance of HPV Genotypes in Head and Neck Squamous Papillomas as Detected by Real-Time PCR and Sanger Sequencing.

Authors:  A Trzcinska; W Zhang; M Gitman; W H Westra
Journal:  Head Neck Pathol       Date:  2019-07-27

Review 5.  Adjuvant antiviral therapy for recurrent respiratory papillomatosis.

Authors:  Neil K Chadha; Adrian James
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 6.  Sudden death by laryngeal polyp: a case report and review of the literature.

Authors:  Jeff Tanguay; Michael Pollanen
Journal:  Forensic Sci Med Pathol       Date:  2008-09-25       Impact factor: 2.007

7.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

8.  Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types.

Authors:  O Martin Williams; Keith W Hart; Eddie C Y Wang; Colin M Gelder
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Multicenter initiative seeking critical genes in respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Craig S Derkay; Suzanne M Leal; Joseph Donfack; Garth D Ehrlich; J Christopher Post
Journal:  Laryngoscope       Date:  2004-02       Impact factor: 3.325

Review 10.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.